Koa Shoji Holdings (9273) Q2 2026 earnings summary

Executive summary

• Net sales for the six months ended December 31, 2025, increased by 3.2% year-over-year to ¥12,654 million, reaching 49.2% of the full-year forecast, with operating profit up 3.4% to ¥3,169 million and profit attributable to owners of parent rising 1.8% to ¥2,085 million.

• Comprehensive income for the period was ¥2,104 million, up 2.5% year-over-year.

• Growth was driven by the API segment, with recently launched products gaining market share and generics volume expanding.

• The manufacture and sales of pharmaceuticals saw mixed results: strong pre-filled syringe sales at Zao Factory, but tablet sales declined due to increased competition.

• A foreign exchange loss impacted profits.

Financial highlights

• Net sales: ¥12,654 million, up 3.2% year-over-year.

• Gross profit: ¥4,358 million, up 4.8% year-over-year.

• Operating profit: ¥3,169 million, up 3.4% year-over-year.

• Ordinary profit: ¥3,113 million, up 1.6% year-over-year.

• Profit attributable to owners: ¥2,085 million, up 1.8% year-over-year.

• Dividend per share increased to 18 yen, up 12.5% year-over-year.

• Basic earnings per share for the period was ¥49.53.

• Total assets as of December 31, 2025, were ¥36,515 million, with net assets at ¥29,551 million.

Outlook and guidance

• Full-year consolidated net sales forecast: ¥25,700 million, up 10.4% year-over-year.

• Operating profit forecast: ¥5,430 million, up 1.4% year-over-year.

• Ordinary profit forecast: ¥5,430 million, up 1.0% year-over-year.

• Profit attributable to owners of parent forecast: ¥3,640 million, up 0.1% year-over-year.

• Basic earnings per share for the full year is forecast at ¥86.42.

• Dividend forecast revised upward to ¥18.00 per share for the fiscal year ending June 30, 2026.

• Long-term target: operating profit of ¥8.0 billion by FYE6/2030.